INT-0091

NCT00002529 📎

Regimen

Experimental
Alternating VDC (vincristine/doxorubicin/cyclophosphamide) + IE (ifosfamide/etoposide)
Control
VDC alone

Population

Newly diagnosed localized or metastatic Ewing sarcoma family of tumors, age <30

Key finding

Adding ifosfamide/etoposide to VDC improved EFS and OS by ~10-15 percentage points in localized Ewing. Metastatic patients did not benefit. Established VDC/IE as the North American standard.

Source: PMID 12594313

Timeline

    Guideline citations

    • NCCN BONE (p.39)